Karus Therapeutics Overview
- Year Founded
-
2004
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Liquidation
Karus Therapeutics General Information
Description
Developer of small molecule drugs designed to promote cancer therapies. The company's small-molecule drugs combine targeted therapy with immunotherapeutic activity for the effective treatment of a diverse range of solid and haematological cancers through oral small-molecule cancer drugs, enabling users to treat immune and inflammatory disorders as well as a diverse range of tumours.
Contact Information
Website
www.karustherapeutics.comCorporate Office
- Building 173, The Innovation Centre
- Harwell Campus, Oxfordshire
- Didcot OX11 0QG
- England, United Kingdom
Corporate Office
- Building 173, The Innovation Centre
- Harwell Campus, Oxfordshire
- Didcot OX11 0QG
- England, United Kingdom
Karus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Bankruptcy: Liquidation | 18-Dec-2023 | Completed | Bankruptcy: Liquidation | |||
| 11. Secondary Transaction - Private | 01-Oct-2021 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 20-Apr-2021 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 06-May-2016 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 21-Sep-2015 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 04-Feb-2014 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 07-Jun-2012 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 04-May-2010 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 06-Apr-2009 | $1.45M | $3.99M | Completed | Startup | |
| 3. Early Stage VC | 01-Jul-2007 | $1.7M | $2.54M | Completed | Startup |
Karus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 177 | $0.013791 | $271.59 | $271.59 | 1x | $271.59 | 0.02% | |
| Ordinary | 6,000 | $0.013791 | $103.43 | $103.43 | 1x | $103.43 | 0.55% |
Karus Therapeutics Comparisons
Industry
Financing
Details
Karus Therapeutics Competitors (123)
One of Karus Therapeutics’s 123 competitors is Biocon Biologics, a Formerly PE-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocon Biologics | Formerly PE-Backed | Bengaluru, India | ||||
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA |
Karus Therapeutics Patents
Karus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202106860-D0 | Histone deacrtylase inhibitors | Inactive | 13-May-2021 | ||
| GB-202009784-D0 | Histone deacetylase inhibitors | Inactive | 26-Jun-2020 | ||
| GB-201912813-D0 | Histone deacetylase inhibitors | Inactive | 05-Sep-2019 | ||
| GB-201909466-D0 | Compounds for treating cancer | Inactive | 01-Jul-2019 | ||
| GB-201909468-D0 | Compounds for treating cancer | Inactive | 01-Jul-2019 | A61K31/5386 |
Karus Therapeutics Signals
Karus Therapeutics FAQs
-
When was Karus Therapeutics founded?
Karus Therapeutics was founded in 2004.
-
Where is Karus Therapeutics headquartered?
Karus Therapeutics is headquartered in Didcot, United Kingdom.
-
What is the size of Karus Therapeutics?
Karus Therapeutics has 6 total employees.
-
What industry is Karus Therapeutics in?
Karus Therapeutics’s primary industry is Biotechnology.
-
Is Karus Therapeutics a private or public company?
Karus Therapeutics is a Private company.
-
What is Karus Therapeutics’s current revenue?
The current revenue for Karus Therapeutics is .
-
How much funding has Karus Therapeutics raised over time?
Karus Therapeutics has raised $101M.
-
Who are Karus Therapeutics’s competitors?
Biocon Biologics, Apexian Pharmaceuticals, Genentech, Attune Pharmaceuticals, and Aro Biotherapeutics are some of the 123 competitors of Karus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process